RCS - Creo Medical Group - MicroBlate™ Fine commercial update

Creo MedicalAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260507:nRSG3223Da&default-theme=true

RNS Number : 3223D  Creo Medical Group PLC  07 May 2026

 

Creo Medical Group plc

("Creo", the "Company" or the "Group")

 

MicroBlate™ Fine commercial update

Creo Medical accelerates US clinical adoption and commercial rollout of
MicroBlate Fine

First breakthrough case delivering targeted therapy for pancreatic lesions

 

Creo Medical Group plc (AIM: CREO), the medical device company specialising in
advanced energy solutions for therapeutic endoscopy, announces a clinical and
commercial update on MicroBlate Fine, its precision microwave ablation
platform, as momentum builds across early US clinical adoption and commercial
rollout.

 

MicroBlate Fine has now crossed the threshold of 50 clinical cases worldwide
across multiple institutions, with particularly strong engagement from leading
US interventional endoscopy centres. MicroBlate Fine is being further
evaluated through an international investigator‑led study across the US,
Europe and Asia‑Pacific, with Banner Health in the US acting as the
principal investigative site. The study is targeting patients with pancreatic
and liver lesions. The first patient was treated in March 2026.

 

In the US, MicroBlate Fine has recently been used to perform the first
endoscopic ultrasound ("EUS") guided microwave ablation of a pancreatic
lesion, highlighting its applicability in complex and previously
difficult‑to‑treat anatomy. MicroBlate Fine enables EUS‑guided microwave
ablation through a flexible 19G needle, providing precise, controlled and
homogeneous energy delivery while integrating seamlessly into existing EUS
workflows. The device is powered by Creo's CROMA™ Advanced Energy Platform.

 

Early adoption by US centres of excellence plays a critical role in
accelerating broader market acceptance and supports future commercial
scale‑up in what represents one of the world's largest therapeutic endoscopy
markets. MicroBlate Fine provides a strategic entry point into high‑value
microwave ablation procedures, with the potential to enhance recurring
revenues and increase utilisation of Creo's broader advanced energy ecosystem,
particularly in the US market.

 

The Company expects continued expansion of site adoption through 2026,
alongside growing US clinical engagement, supporting both near‑term revenue
generation and longer‑term market penetration in advanced therapeutic
endoscopy.

 

Dr Shailendra Singh, Director of Advanced Endoscopy and Associate Professor at
West Virginia University, said: "The ability to deliver microwave ablation
under EUS guidance offers precise, controlled and homogeneous energy delivery,
enabling targeted therapy for pancreatic lesions. Technologies such as this
expand the reach of interventional EUS and have the potential to significantly
broaden treatment options for patients."

 

Craig Gulliford, Chief Executive Officer of Creo Medical, said: "Early US
clinical engagement with MicroBlate Fine, combined with progressing
international studies and encouraging commercial traction, reinforces our
belief that this product can become an important growth driver for the Group.
With attractive per‑procedure economics and clear portfolio pull‑through,
MicroBlate Fine strengthens our position in therapeutic endoscopy and enhances
our commercial opportunity.

 

"As always, patient benefits come first and the fact that previously very sick
patients are being put back on to routine follow-up with no evidence of
disease at their first follow-up consultation is extremely rewarding for the
whole Creo Team."

 

For further information please contact:

 

 Creo Medical Group plc                                                         www.creomedical.com
                                                                                (https://protect.checkpoint.com/v2/___http:/www.creomedical.com/___.YzJ1OmludHVpdGl2ZTpjOm86NWJlYzBmMzJjY2MyZTBiZWFkNmJkZmVmNzdhM2MwMTI6NjoyYWU4OjczNzQyNWUwODBjYTEwNzAxYWMzNWEyZDQ3YzI1ZmEwYWMzYTc4M2Q2M2NjYzEyNTQwZWM3ODc4NTk3NTE4YTQ6cDpUOk4)
 Richard Craven, Company Secretary                                              Via Walbrook PR

 Deutsche Numis (Nominated Adviser, Joint Broker and Financial Adviser)         +44 (0)20 7260 1000

 Duncan Monteith / Sher Shah

 Shore Capital (Joint Broker)                                                   +44 (0)20 7408 4090

 Daniel Bush / Lucy Bowden

 Walbrook PR Ltd                       Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com (mailto:creo@walbrookpr.com)
 Paul McManus / Alice Woodings         Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654

 

 

About Creo Medical

Creo is a medical device company focused on the development and
commercialisation of minimally invasive electrosurgical devices, bringing
advanced energy to endoscopy.

 

The Company's vision is to improve patient outcomes through the development
and commercialisation of a suite of electrosurgical medical devices, each
enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA
powered by Kamaptive full-spectrum adaptive technology to optimise surgical
capability and patient outcomes. Kamaptive is a seamless, intuitive
integration of multi-modal energy sources, optimised to dynamically adapt to
patient tissue during procedures such as resection, dissection, coagulation,
and ablation of tissue. Kamaptive technology provides clinicians with
increased flexibility, precision and controlled surgical solutions. CROMA
currently delivers bipolar radiofrequency ("RF") energy for precise localised
cutting and focused high frequency microwave ("MW") energy for controlled
coagulation and ablation via a single accessory port. This technology,
combined with the Group's range of patented electrosurgical devices, is
designed to provide clinicians with flexible, accurate and controlled clinical
solutions. The Directors believe the Company's technology can impact the
landscape of surgery and endoscopy by providing a safer, less invasive and
more cost-efficient option for procedures.

 

For more information, please refer to the website www.creomedical.com
(https://protect.checkpoint.com/v2/___http:/www.creomedical.com/___.YzJ1OmludHVpdGl2ZTpjOm86NWJlYzBmMzJjY2MyZTBiZWFkNmJkZmVmNzdhM2MwMTI6NjoyYWU4OjczNzQyNWUwODBjYTEwNzAxYWMzNWEyZDQ3YzI1ZmEwYWMzYTc4M2Q2M2NjYzEyNTQwZWM3ODc4NTk3NTE4YTQ6cDpUOk4)

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAAKABQKBKBNPK



            Copyright 2019 Regulatory News Service, all rights reserved